IVI RMA Global and Lavima Fertility Join Forces in Research, Fertility Treatments

 

 

VALENCIA, Spain and BRUSSELS, Radarseluma.Disway.Id -- Seeking alternatives to obtain oocytes without ovarian stimulation is a pioneering line of research in reproductive medicine.

 

The inconveniences that the process of ovarian stimulation can generate are a current barrier for some women and couples who are considering starting a reproductive treatment. In fact, 1 out of every 5 couples do not start the search for a second child for this reason.

 

BACA JUGA:Mitsubishi Pajero Sport, SUV Handal dan Mewah Kombinasi Fitur Sistem Terbaru Desain Lebih Cnaggih

BACA JUGA:BTS Di Ulu Talo Sudah Beroperasi, Ulu Seluma Bebas Blank Spot

 

Ovarian stimulation is the initial part of assisted reproduction treatments, and it is the phase of infertility treatments in which the least relevant advances have been achieved to date. It is one of the main psychological barriers for women when deciding to begin this path towards motherhood. Many of them are concerned about how this process may affect them physically and emotionally.

 

With the aim of making progress in this field, IVI RMA GLOBAL has signed an exclusive agreement with Lavima Fertility, Inc., a US company in the fertility sector which owns the rights to CAPA-IVM, a completely novel hormone-free fertility treatment technology. Together, IVI RMA Global and Lavima Fertility have opened a pioneering line of research aimed at eliminating ovarian stimulation in women who wish to begin assisted reproduction or egg vitrification treatment.

 

"We are aware that the ovarian stimulation phase can be faced with some anxiety and can be a brake on the decision to begin treatment. For this reason, at IVI and together with Lavima Fertility, we have taken the initiative and we are going to challenge science to try to optimize this very delicate part of the treatment for some patients," explains Dr. Nuria Pellicer, gynecologist at IVI Valencia.

Sumber: